Cargando…

Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS

Detalles Bibliográficos
Autores principales:	Gregory, Gareth P., Dickinson, Michael, Yannakou, Costas K., Wong, Jonathan, Blombery, Piers, Corboy, Greg, Kats, Lev, Crozier, Tim M.E., Kumar, Beena, Prince, H. Miles, Opat, Stephen S., Shortt, Jake
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746031/ https://www.ncbi.nlm.nih.gov/pubmed/31723826 http://dx.doi.org/10.1097/HS9.0000000000000187

Ejemplares similares

Durable response of therapy-related MDS/AML with concomitant Waldenström’s macroglobulinemia treated with venetoclax and azacitidine
por: Hirano, Mitsuhito, et al.
Publicado: (2022)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax
por: Ehsan, Hamid, et al.
Publicado: (2022)

The effect of azacitidine therapy on the M protein of MDS patients with concomitant MGUS
por: Oka, Satoko, et al.
Publicado: (2018)

Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations
por: Wong, Jonathan, et al.
Publicado: (2020)

TET2 deficiency promotes MDS-associated leukemogenesis
por: Huang, Feiteng, et al.
Publicado: (2022)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
por: Jilg, Stefanie, et al.
Publicado: (2019)

Effect of 5-Azacitidine Treatment on Redox Status and Inflammatory Condition in MDS Patients
por: Montes, Paola, et al.
Publicado: (2022)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Correction: TET2 deficiency promotes MDS-associated leukemogenesis
por: Huang, Feiteng, et al.
Publicado: (2023)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
por: DeZern, A., et al.
Publicado: (2022)

Lenalidomide induced durable remission in a patient with MDS/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome
por: Alshaban, Ahmed, et al.
Publicado: (2018)

AITL: Adversarial Inductive Transfer Learning with input and output space adaptation for pharmacogenomics
por: Sharifi-Noghabi, Hossein, et al.
Publicado: (2020)

Favorable outcomes of DDX41‐mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide
por: Tiong, Ing S., et al.
Publicado: (2023)

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
por: Cluzeau, Thomas, et al.
Publicado: (2012)

Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders
por: Polgarova, Kamila, et al.
Publicado: (2017)

ASXL1 c.1934dup;p.Gly646Trpfs*12—a true somatic alteration requiring a new approach
por: Yannakou, Costas K., et al.
Publicado: (2017)

Epstein-Barr Virus (EBV) Is Mostly Latent and Clonal in Angioimmunoblastic T Cell Lymphoma (AITL)
por: Bahri, Racha, et al.
Publicado: (2022)

Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia
por: Stölzel, Friedrich, et al.
Publicado: (2023)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
por: Zeidan, Amer M., et al.
Publicado: (2018)

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease
por: Tobiasson, Magnus, et al.
Publicado: (2017)

HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML
por: Huang, Feiteng, et al.
Publicado: (2020)

IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
por: Leisch, Michael, et al.
Publicado: (2020)

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019)

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
por: Kenealy, Melita, et al.
Publicado: (2019)

An assessment of acute insecticide toxicity loading (AITL) of chemical pesticides used on agricultural land in the United States
por: DiBartolomeis, Michael, et al.
Publicado: (2019)

Comprehensive Epstein-Barr Virus Transcriptome by RNA-Sequencing in Angioimmunoblastic T Cell Lymphoma (AITL) and Other Lymphomas
por: Bayda, Nader, et al.
Publicado: (2021)

Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine
por: Miltiades, P, et al.
Publicado: (2014)

Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent
por: Niscola, Pasquale, et al.
Publicado: (2015)

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes
por: Follo, Matilde Y., et al.
Publicado: (2019)

P1678: INTERVENTIONS AND THERAPY AT END OF LIFE IN HAEMATOLOGICAL MALIGNANCY: A RETROSPECTIVE COHORT STUDY ON HEALTHCARE UTILISATION
por: Shaw, Briony, et al.
Publicado: (2023)

PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS
por: Rajakumaraswamy, N., et al.
Publicado: (2022)

Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL)
por: Sokol, Kelsey, et al.
Publicado: (2019)

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts
por: Garcia-Manero, G, et al.
Publicado: (2017)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
por: Minarik, L., et al.
Publicado: (2022)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)

Impact of coronavirus disease 2019 (COVID-19) pandemic isolation measures on the rate of non–COVID-19 infections in hematology patients
por: Miller, Jemima H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k4nseum26fbikt22fbc9q64d62